Close X
Attorney Spotlight

Learn about Richard Arnholt's diverse government contracts practice and why he chose to pursue a career in the legal field. Read more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

In June 2017, Pinnacle Financial Partners, Inc. (NASDAQ: PNFP) closed a $1.9 billion merger with BNC Bancorp (NASDAQ: BNCN) pursuant to which BNC merged with and into Pinnacle. With the completion of the transaction, Pinnacle becomes a Top 50 U.S. Bank. The merger will create a four state footprint concentrated in 12 of the largest urban markets in the Southeast. 

Bass, Berry & Sims has served Pinnacle as primary corporate and securities counsel for more than 15 years and served as counsel on the transaction. Our attorneys were involved in all aspects related to the agreement, including tax, employee benefits and litigation. 

Read more details about the transaction here.

Pinnacle Financial Partners logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Regulation A+

It seems that lately there has been a noticeable uptick in Regulation A+ activity, including several recent Reg A+ securities offerings where the stock now successfully trades on national exchanges. In light of this activity, we have published a set of FAQs about Regulation A+ securities offerings to help companies better understand this "mini-IPO" offering process, as well as pros and cons compared to a traditional underwritten IPO.

Read now

Defense of Salix Pharmaceuticals in Multiple Jurisdictions

Client Type: Public Company

We represented Salix Pharmaceuticals in cases in multiple jurisdictions alleging renal failure suffered as a result of using a pharmaceutical product. The plaintiffs allegedly suffered renal failure after using a cleansing product that is routinely prescribed prior to a colonoscopy procedure. We conducted the initial investigation into the company's new drug application, amended warnings, adverse event reports, and other pertinent documents. We collected and preserved the pertinent documents through the use of a complimentary and secure extranet for the client. We identified and interviewed the key company executives and employees involved in the issues that were pertinent to the litigation. These cases focused on the adequacy of the warning labels that accompanied the product and alternative products that were less effective but arguably carried less risk to the patient. One case was dismissed after we deposed the plaintiff and obtained an admission during that deposition that she had just perjured herself after being confronted with a document that contradicted her testimony. Other cases were successfully resolved.

Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) is a specialist pharmaceutical company that develops drugs and medical devices to prevent and treat various gastrointestinal disorders.

You Also May Be Interested In:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.